SCHEMBL30101464

SCHEMBL30101464

c1cc2c(c(OC3CCOCC3)c1)CNC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 1/20 0.43
BAZ2B Q9UIF8 1/20 0.43
SYK P43405 1/20 0.37
HRH1 P35367 3/20 0.36
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
TIPARP Q7Z3E1 1/20 0.34
CHKA P35790 1/20 0.34
SLC6A2 P23975 3/20 0.33
SLC6A3 Q01959 3/20 0.33
HTR1A P08908 2/20 0.33
SLC6A4 P31645 2/20 0.33
IKBKE Q14164 2/20 0.33
QPCT Q16769 1/20 0.33
QPCTL Q9NXS2 1/20 0.33
TBK1 Q9UHD2 2/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
NR1I2 O75469 1/20 0.33
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30156626 0.91 NTRK1 (0.38) KAT2BBAZ2BQPCTQPCTL
Hydrochloric Acid SCHEMBL31014071 0.90 NTRK1 (0.37) KAT2BBAZ2BQPCTQPCTL
SCHEMBL29942325 0.84 HRH1 (0.51) HRH1TIPARPSLC6A2SLC6A3HTR1A
SCHEMBL30101544 0.83 QPCT (0.37) HTR2CHTR2BTIPARPSLC6A2SLC6A3
SCHEMBL30101397 0.79 HTR1A (0.50) HRH1HTR2CHTR2BTIPARPSLC6A2
Hydrochloric Acid SCHEMBL31013890 0.78 PNMT (0.42)
SCHEMBL30101583 0.74 KDM4E (0.34)
SCHEMBL30156514 0.74 SLC6A4 (0.33) SLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL29168668 0.74 SLC6A4 (0.33) SLC6A2SLC6A3HTR1ASLC6A4
SCHEMBL24913829 0.73 TIPARP (0.43) TIPARPQPCTQPCTL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 US disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 US disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KAT2B 1487/4885BAZ2B 79/4885SYK 3669/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 KAT2B 1487/4885BAZ2B 79/4885SYK 3669/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 KAT2B 1487/4885BAZ2B 79/4885SYK 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.